相关实验视频

Updated: Jan 13, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

针对NAT10-HDAC4正反循环,可以抵消乳腺癌免疫抑制的作用

Xin Ma¹, Shengye Jin¹, Xingda Zhang¹

¹Department of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China.

Journal of experimental & clinical cancer research : CR

|January 8, 2026

概括

N-乙转移酶10 (NAT10) 通过HDAC4.4的自我强化循环驱动乳腺癌的进展和免疫逃避. 针对这个NAT10/HDAC4轴可能会改善乳腺癌治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

N-乙转移酶10 (NAT10) 和其N4-乙基提丁 (ac4C) 修饰与瘤进展有关.
对于NAT10在乳腺癌进展中的特定作用和机制尚不清楚.

研究的目的:

研究NAT10在乳腺癌进展和免疫逃避中的作用和机制.
探索针对NAT10通路用于乳腺癌治疗的潜力.

主要方法:

使用临床样本和公共数据库分析了NAT10表达和乳腺癌的预后价值.
进行了体外和体内功能测试,以评估NAT10对瘤生长和免疫规避的影响.
利用RNA免疫沉降 (RIP),ac4CRNA免疫沉降 (acRIP) 和共同免疫沉降 (Co-IP) 来研究NAT10-HDAC4相互作用和NF-κB/PD-L1调节.

主要成果:

乳腺癌中NAT10表达升高,与预后不佳相关.
NAT10通过稳定其mRNA来增强HDAC4的表达,而HDAC4稳定NAT10蛋白质,从而创建一个反循环.
NAT10/HDAC4轴激活NF-κB信号,增加PD-L1表达并促进免疫逃逸.
抑制这一轴降低PD-L1并增强抗瘤免疫力.

结论:

一个自我强化的NAT10/HDAC4信号电路促进乳腺癌的进展和免疫规避.
针对NAT10提供了一种潜在的治疗策略,以克服免疫抑制并改善乳腺癌患者的治疗结果.

关键词:

在 HDAC4 中,HDAC4 是免疫抑制是一种免疫抑制.在 NAT10 中,NAT10 包含了NAT10.在PD-L1中.在 ac4C 修改的过程中,

更多相关视频

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...